查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1922717

日本肺動脈高壓治療市場規模、佔有率、趨勢及預測（按藥物類別、給藥途徑、最終用戶和地區分類，2026-2034年）

Japan Pulmonary Arterial Hypertension Drugs Market Size, Share, Trends and Forecast by Drug Class, Route of Administration, End User, and Region, 2026-2034
出版日期: | 出版商: IMARC | 英文 115 Pages | 商品交期: 5-7個工作天內

價格
簡介目錄

2025年，日本肺動脈高壓治療藥物市場規模達4.97億美元。 IMARC Group預測，到2034年，該市場規模將達到7.958億美元，2026年至2034年的複合年成長率為5.37%。推動市場成長的關鍵因素包括：人們對該疾病的認知不斷提高、診斷技術的進步、新治療方法的推出、對個人化醫療的日益重視、研發方面的大量投資以及促進藥物快速核准的監管支持。

日本肺動脈高壓治療市場趨勢：

標靶治療和個人化醫療的進展

推動日本肺動脈高壓（PAH）治療市場成長的關鍵趨勢是日益重視標靶治療和個人化醫療。這些先進治療方法旨在透過特異性靶向參與疾病進展的分子路徑（例如內皮素、一氧化氮和前列腺環素）來解決肺動脈高壓的根本原因。生物標記識別和基因組檢測技術的進步推動了個人化治療的興起，使得根據患者的基因譜進行更客製化的治療成為可能，從而提高療效並最大限度地減少副作用。這一上升趨勢反映了PAH治療的持續發展，其目標是透過精準醫療改善患者的治療效果。

疾病意識提高和早期診斷取得進展

大眾對肺動脈高壓（PAH）的認知度不斷提高，顯著推動了日本PAH治療市場的成長。 PAH曾因其症狀特異性難以診斷，但如今患者和醫療服務提供者都已普遍認知到該疾病。主導的宣傳活動，廣泛普及了公眾和醫療專業人員對早期診斷和適當介入重要性的認知。同時，心臟超音波圖、右心導管檢查和生物標記等診斷技術的進步，使得疾病的早期發現成為可能，從而推動了對PAH治療需求的成長。此外，日本PAH確診患者人數也逐漸增加，這印證了公眾認知度提高和早期發現的正面影響。這種認知度的提升正在刺激治療需求，並加速市場進一步擴張。

本報告解答的關鍵問題

  • 日本肺動脈高壓治療市場目前發展狀況如何？未來幾年又將如何發展？
  • 日本肺動脈高壓治療市場依藥物類別是如何分類的？
  • 日本肺動脈高壓治療市場依給藥途徑分類的組成是怎樣的？
  • 日本肺動脈高壓治療市場依最終用戶分類的市場區隔如何？
  • 日本肺動脈高壓治療市場按地區分類的情況如何？
  • 請介紹日本肺動脈高壓治療市場價值鏈的各個環節。
  • 日本肺動脈高壓治療市場的主要促進因素和挑戰是什麼？
  • 日本肺動脈高壓治療市場的結構是怎麼樣的？主要參與者有哪些？
  • 日本肺動脈高壓治療藥物市場競爭程度如何？

目錄

第1章：序言

第2章：調查範圍與調查方法

  • 調查目標
  • 相關利益者
  • 數據來源
  • 市場估值
  • 調查方法

第3章執行摘要

第4章：日本肺動脈高壓治療市場－簡介

  • 概述
  • 市場動態
  • 產業趨勢
  • 競爭資訊

第5章 日本肺動脈高壓治療市場概述

  • 過去和當前的市場趨勢（2020-2025）
  • 市場預測（2026-2034）

第6章：日本肺動脈高壓治療市場－依藥物類別細分

  • 內皮素受體拮抗劑（ERA）
  • 血管擴張劑
  • 磷酸二酯酶-5 (PDE-5) 抑制劑
  • 可溶性鳥苷酸環化酶（SGC）促效劑
  • 鈣離子通道阻斷劑（CCBs）
  • 前列腺環素和前列腺環素類似物
  • 其他

第7章 日本肺動脈高壓治療市場－依給藥途徑細分

  • 吸入
  • 注射
  • 口服

第8章：日本肺動脈高壓治療市場－依最終用戶細分

  • 醫院
  • 診所
  • 其他

第9章：日本肺動脈高壓治療市場：依地區分類

  • 關東地區
  • 關西、近畿地區
  • 中部地區
  • 九州和沖繩地區
  • 東北部地區
  • 中國地區
  • 北海道地區
  • 四國地區

第10章：日本肺動脈高壓治療市場：競爭格局

  • 概述
  • 市場結構
  • 市場公司定位
  • 關鍵成功策略
  • 競爭對手儀錶板
  • 企業估值象限

第11章主要企業概況

第12章：日本肺動脈高壓治療市場：產業分析

  • 促進因素、限制因素和機遇
  • 波特五力分析
  • 價值鏈分析

第13章附錄

簡介目錄
Product Code: SR112026A34767

The Japan pulmonary arterial hypertension drugs market size reached USD 497.0 Million in 2025 . Looking forward, IMARC Group expects the market to reach USD 795.8 Million by 2034 , exhibiting a growth rate (CAGR) of 5.37% during 2026-2034 . The increased disease awareness, advancements in diagnostic technologies, introduction of novel therapies, a growing focus on personalized medicines, substantial research and development (R&D) investments, and regulatory support facilitating expedited drug approvals are among the key factors driving the market growth.

JAPAN PULMONARY ARTERIAL HYPERTENSION DRUGS MARKET TRENDS:

Advancements in Targeted Therapies and Personalized Medicine

A key trend propelling the growth of Japan's pulmonary arterial hypertension (PAH) drugs market is the increasing focus on targeted therapies and personalized medicine. These advanced treatments are designed to address the root causes of pulmonary arterial hypertension by specifically targeting molecular pathways such as endothelin, nitric oxide, and prostacyclin, which are involved in disease progression. The rise of personalized treatments, fueled by advances in biomarker identification and genomic testing, allows for more customized therapies that are tailored to a patient's genetic profile, enhancing efficacy and minimizing side effects. This upward trend reflects the ongoing evolution in PAH treatment, aimed at improving patient outcomes through precision medicine.

To get more information on this market Request Sample

Increase in Disease Awareness and Early Diagnosis

Increasing awareness about PAH is significantly contributing to the growth of Japan's PAH drugs market. Historically underdiagnosed due to its non-specific symptoms, PAH is now being recognized more widely by both patients and healthcare providers. Public awareness campaigns led by health organizations, hospitals, and pharmaceutical companies are educating the public and medical professionals about the importance of early diagnosis and timely intervention. In parallel, advancements in diagnostic technologies, including echocardiography, right heart catheterization, and biomarkers, have enabled earlier detection of the disease, driving greater demand for PAH therapies. In addition to this, the number of diagnosed PAH patients in Japan is gradually increasing, underscoring the positive impact of heightened awareness and early detection. This growing recognition is fueling the demand for treatment, further catalyzing the market's expansion.

JAPAN PULMONARY ARTERIAL HYPERTENSION DRUGS MARKET SEGMENTATION:

Drug Class Insights:

  • Endothelin Receptor Antagonists (ERAs)
  • Vasodilators
  • Phosphodiesterase-5 (PDE-5) Inhibitors
  • Soluble Guanylate Cyclase (SGC) Stimulators
  • Calcium Channel Blockers (CCBs)
  • Prostacyclin and Prostacyclin Analogs
  • Others
  • Endothelin Receptor Antagonists (ERAs)
  • Vasodilators
  • Phosphodiesterase-5 (PDE-5) Inhibitors
  • Soluble Guanylate Cyclase (SGC) Stimulators
  • Calcium Channel Blockers (CCBs)
  • Prostacyclin and Prostacyclin Analogs
  • Others

Route of Administration Insights:

  • Inhalation
  • Injectable
  • Oral Administration
  • Inhalation
  • Injectable
  • Oral Administration

End User Insights:

  • Access the comprehensive market breakdown Request Sample
  • Hospitals
  • Clinics
  • Others
  • Hospitals
  • Clinics
  • Others

Regional Insights:

  • Kanto Region
  • Kansai/Kinki Region
  • Central/Chubu Region
  • Kyushu-Okinawa Region
  • Tohoku Region
  • Chugoku Region
  • Hokkaido Region
  • Shikoku Region
  • Kanto Region
  • Kansai/Kinki Region
  • Central/Chubu Region
  • Kyushu-Okinawa Region
  • Tohoku Region
  • Chugoku Region
  • Hokkaido Region
  • Shikoku Region
  • The report has also provided a comprehensive analysis of all the major regional markets, which include Kanto Region, Kansai/Kinki Region, Central/Chubu Region, Kyushu-Okinawa Region, Tohoku Region, Chugoku Region, Hokkaido Region, and Shikoku Region.

COMPETITIVE LANDSCAPE:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

  • KEY QUESTIONS ANSWERED IN THIS REPORT
  • How has the Japan pulmonary arterial hypertension drugs market performed so far and how will it perform in the coming years?
  • What is the breakup of the Japan pulmonary arterial hypertension drugs market on the basis of drug class?
  • What is the breakup of the Japan pulmonary arterial hypertension drugs market on the basis of route of administration?
  • What is the breakup of the Japan pulmonary arterial hypertension drugs market on the basis of end user?
  • What is the breakup of the Japan pulmonary arterial hypertension drugs market on the basis of region?
  • What are the various stages in the value chain of the Japan pulmonary arterial hypertension drugs market?
  • What are the key driving factors and challenges in the Japan pulmonary arterial hypertension drugs?
  • What is the structure of the Japan pulmonary arterial hypertension drugs market and who are the key players?
  • What is the degree of competition in the Japan pulmonary arterial hypertension drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Japan Pulmonary Arterial Hypertension Drugs Market - Introduction

  • 4.1 Overview
  • 4.2 Market Dynamics
  • 4.3 Industry Trends
  • 4.4 Competitive Intelligence

5 Japan Pulmonary Arterial Hypertension Drugs Market Landscape

  • 5.1 Historical and Current Market Trends (2020-2025)
  • 5.2 Market Forecast (2026-2034)

6 Japan Pulmonary Arterial Hypertension Drugs Market - Breakup by Drug Class

  • 6.1 Endothelin Receptor Antagonists (ERAs)
    • 6.1.1 Overview
    • 6.1.2 Historical and Current Market Trends (2020-2025)
    • 6.1.3 Market Forecast (2026-2034)
  • 6.2 Vasodilators
    • 6.2.1 Overview
    • 6.2.2 Historical and Current Market Trends (2020-2025)
    • 6.2.3 Market Forecast (2026-2034)
  • 6.3 Phosphodiesterase-5 (PDE-5) Inhibitors
    • 6.3.1 Overview
    • 6.3.2 Historical and Current Market Trends (2020-2025)
    • 6.3.3 Market Forecast (2026-2034)
  • 6.4 Soluble Guanylate Cyclase (SGC) Stimulators
    • 6.4.1 Overview
    • 6.4.2 Historical and Current Market Trends (2020-2025)
    • 6.4.3 Market Forecast (2026-2034)
  • 6.5 Calcium Channel Blockers (CCBs)
    • 6.5.1 Overview
    • 6.5.2 Historical and Current Market Trends (2020-2025)
    • 6.5.3 Market Forecast (2026-2034)
  • 6.6 Prostacyclin and Prostacyclin Analogs
    • 6.6.1 Overview
    • 6.6.2 Historical and Current Market Trends (2020-2025)
    • 6.6.3 Market Forecast (2026-2034)
  • 6.7 Others
    • 6.7.1 Historical and Current Market Trends (2020-2025)
    • 6.7.2 Market Forecast (2026-2034)

7 Japan Pulmonary Arterial Hypertension Drugs Market - Breakup by Route of Administration

  • 7.1 Inhalation
    • 7.1.1 Overview
    • 7.1.2 Historical and Current Market Trends (2020-2025)
    • 7.1.3 Market Forecast (2026-2034)
  • 7.2 Injectable
    • 7.2.1 Overview
    • 7.2.2 Historical and Current Market Trends (2020-2025)
    • 7.2.3 Market Forecast (2026-2034)
  • 7.3 Oral Administration
    • 7.3.1 Overview
    • 7.3.2 Historical and Current Market Trends (2020-2025)
    • 7.3.3 Market Forecast (2026-2034)

8 Japan Pulmonary Arterial Hypertension Drugs Market - Breakup by End User

  • 8.1 Hospitals
    • 8.1.1 Overview
    • 8.1.2 Historical and Current Market Trends (2020-2025)
    • 8.1.3 Market Forecast (2026-2034)
  • 8.2 Clinics
    • 8.2.1 Overview
    • 8.2.2 Historical and Current Market Trends (2020-2025)
    • 8.2.3 Market Forecast (2026-2034)
  • 8.3 Others
    • 8.3.1 Historical and Current Market Trends (2020-2025)
    • 8.3.2 Market Forecast (2026-2034)

9 Japan Pulmonary Arterial Hypertension Drugs Market - Breakup by Region

  • 9.1 Kanto Region
    • 9.1.1 Overview
    • 9.1.2 Historical and Current Market Trends (2020-2025)
    • 9.1.3 Market Breakup by Drug Class
    • 9.1.4 Market Breakup by Route of Administration
    • 9.1.5 Market Breakup by End User
    • 9.1.6 Key Players
    • 9.1.7 Market Forecast (2026-2034)
  • 9.2 Kansai/Kinki Region
    • 9.2.1 Overview
    • 9.2.2 Historical and Current Market Trends (2020-2025)
    • 9.2.3 Market Breakup by Drug Class
    • 9.2.4 Market Breakup by Route of Administration
    • 9.2.5 Market Breakup by End User
    • 9.2.6 Key Players
    • 9.2.7 Market Forecast (2026-2034)
  • 9.3 Central/ Chubu Region
    • 9.3.1 Overview
    • 9.3.2 Historical and Current Market Trends (2020-2025)
    • 9.3.3 Market Breakup by Drug Class
    • 9.3.4 Market Breakup by Route of Administration
    • 9.3.5 Market Breakup by End User
    • 9.3.6 Key Players
    • 9.3.7 Market Forecast (2026-2034)
  • 9.4 Kyushu-Okinawa Region
    • 9.4.1 Overview
    • 9.4.2 Historical and Current Market Trends (2020-2025)
    • 9.4.3 Market Breakup by Drug Class
    • 9.4.4 Market Breakup by Route of Administration
    • 9.4.5 Market Breakup by End User
    • 9.4.6 Key Players
    • 9.4.7 Market Forecast (2026-2034)
  • 9.5 Tohoku Region
    • 9.5.1 Overview
    • 9.5.2 Historical and Current Market Trends (2020-2025)
    • 9.5.3 Market Breakup by Drug Class
    • 9.5.4 Market Breakup by Route of Administration
    • 9.5.5 Market Breakup by End User
    • 9.5.6 Key Players
    • 9.5.7 Market Forecast (2026-2034)
  • 9.6 Chugoku Region
    • 9.6.1 Overview
    • 9.6.2 Historical and Current Market Trends (2020-2025)
    • 9.6.3 Market Breakup by Drug Class
    • 9.6.4 Market Breakup by Route of Administration
    • 9.6.5 Market Breakup by End User
    • 9.6.6 Key Players
    • 9.6.7 Market Forecast (2026-2034)
  • 9.7 Hokkaido Region
    • 9.7.1 Overview
    • 9.7.2 Historical and Current Market Trends (2020-2025)
    • 9.7.3 Market Breakup by Drug Class
    • 9.7.4 Market Breakup by Route of Administration
    • 9.7.5 Market Breakup by End User
    • 9.7.6 Key Players
    • 9.7.7 Market Forecast (2026-2034)
  • 9.8 Shikoku Region
    • 9.8.1 Overview
    • 9.8.2 Historical and Current Market Trends (2020-2025)
    • 9.8.3 Market Breakup by Drug Class
    • 9.8.4 Market Breakup by Route of Administration
    • 9.8.5 Market Breakup by End User
    • 9.8.6 Key Players
    • 9.8.7 Market Forecast (2026-2034)

10 Japan Pulmonary Arterial Hypertension Drugs Market - Competitive Landscape

  • 10.1 Overview
  • 10.2 Market Structure
  • 10.3 Market Player Positioning
  • 10.4 Top Winning Strategies
  • 10.5 Competitive Dashboard
  • 10.6 Company Evaluation Quadrant

11 Profiles of Key Players

  • 11.1 Company A
    • 11.1.1 Business Overview
    • 11.1.2 Products Offered
    • 11.1.3 Business Strategies
    • 11.1.4 SWOT Analysis
    • 11.1.5 Major News and Events
  • 11.2 Company B
    • 11.2.1 Business Overview
    • 11.2.2 Products Offered
    • 11.2.3 Business Strategies
    • 11.2.4 SWOT Analysis
    • 11.2.5 Major News and Events
  • 11.3 Company C
    • 11.3.1 Business Overview
    • 11.3.2 Products Offered
    • 11.3.3 Business Strategies
    • 11.3.4 SWOT Analysis
    • 11.3.5 Major News and Events
  • 11.4 Company D
    • 11.4.1 Business Overview
    • 11.4.2 Products Offered
    • 11.4.3 Business Strategies
    • 11.4.4 SWOT Analysis
    • 11.4.5 Major News and Events
  • 11.5 Company E
    • 11.5.1 Business Overview
    • 11.5.2 Products Offered
    • 11.5.3 Business Strategies
    • 11.5.4 SWOT Analysis
    • 11.5.5 Major News and Events

12 Japan Pulmonary Arterial Hypertension Drugs Market - Industry Analysis

  • 12.1 Drivers, Restraints, and Opportunities
    • 12.1.1 Overview
    • 12.1.2 Drivers
    • 12.1.3 Restraints
    • 12.1.4 Opportunities
  • 12.2 Porters Five Forces Analysis
    • 12.2.1 Overview
    • 12.2.2 Bargaining Power of Buyers
    • 12.2.3 Bargaining Power of Suppliers
    • 12.2.4 Degree of Competition
    • 12.2.5 Threat of New Entrants
    • 12.2.6 Threat of Substitutes
  • 12.3 Value Chain Analysis

13 Appendix